MEMBER LOGIN: Your Email: Password: Remember Me
Forgot Your Password or would like to register?
JNJ Johnson & Johnson
As Of 1/22/2019 7:12:00 PM
Current Price$128.80
Current Rating1
Return Since 2/2016
Johnson & Johnson 30.10 %
S&P 50035.69 %
VFS Rating Analysis
Market ReturnAverage
return vs market
Related Links
Company News
Earnings Call Transcripts
Options Chain
Options Pricing History
For current estimates, historical performance information and more, Log in to your account.

Monthly Performance and Prediction History
Below is the monthly performance history for this security and the monthly change as compared to the stock market for this security. When a row is highlighted in green, it is identifying a stock that the model predict will outperform the portfolio for that month. When a row is highlighted in red, it is identifying a stock that the model predicted will underperform for the month. No highlight indicates the model is neutral on the stock. These predictions are always recorded at the beginning of the month, and table below shows the resulting return for the month.
DateVFS RatingPredictionRating PriceSubsequent
% Increase
Market %
Increase *
1-01-20192 $129.05   
12-01-20181 $146.90-12.15%-9.33%-2.82%
11-01-20181 $139.995.58%1.85%3.72%
10-01-20181 $138.171.32%-6.91%8.23%
8-01-20182 $132.522.32%3.19%-0.88%
5-01-20183 $126.49-4.72%2.43%-7.15%
4-01-20182 $128.15-1.30%0.52%-1.81%
3-01-20182 $129.88-1.33%-3.13%1.80%
* As measured by the performance of the S&P 500 for the month.

JNJ12Should You Load Up on JNJ Stock Before Earnings? ( 12:00:00 PM
JNJ123 Earnings Reports to Watch Next Week ( 9:30:00 AM
JNJ12Johnson & Johnson Announces Research Study with Apple Watch to Help Improve AFib Outcomes Including Stroke Prevention ( 5:30:00 AM
JNJ12Johnson & Johnson Completes Acquisition of Ci:z Holdings Co., Ltd. ( 4:00:00 AM
JNJ12Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know ( 2:45:00 PM
JNJ12Cannabis Company Avicanna Eyes Canadian IPO ( 8:43:00 AM
JNJ12Johnson & Johnson (JNJ) Earnings Expected to Grow: Should You Buy? ( 7:30:00 AM
JNJ12See what the IHS Markit Score report has to say about Johnson & Johnson. ( 5:01:00 AM
JNJ12ATTENTION JNJ EMPLOYEES: Zamansky LLC Investigates Possible ERISA Violations in the Johnson & Johnson Savings Plan ( 12:08:00 PM
JNJ12Johnson & Johnson Recommends Rejection Of Below-Market "Mini-Tender" Offer By Peer & Peri LLC ( 2:00:00 PM
JNJ12Johnson & Johnson Announces completion of Offer for Ci:z Holdings Co., Ltd. ( 4:00:00 AM
JNJ12Johnson & Johnson raises U.S. prices on around two dozen drugs ( 3:31:00 PM
JNJ12Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know ( 2:45:00 PM
JNJ12See what the IHS Markit Score report has to say about Johnson & Johnson. ( 5:01:00 AM
JNJ11Johnson & Johnson (JNJ) Q4 2018 Earnings Conference Call Transcript ( 7:44:00 PM
JNJ115 Top Stock Trades for Wednesday: JNJ, CMG, MO, EBAY ( 12:47:00 PM
JNJ7The Zacks Analyst Blog Highlights: Apple, Johnson & Johnson, Amazon and Alphabet ( 4:39:00 AM
JNJ7The 5 Big Earnings Reports Jim Cramer Will Be Watching This Week ( 4:30:00 AM
JNJ73 Things to Watch in the Stock Market This Week ( 11:02:00 AM
JNJ7Better Buy: AbbVie vs. Johnson & Johnson ( 8:30:00 AM
JNJ7JOHNSON & JOHNSON INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Johnson & Johnson - JNJ ( 7:50:00 PM
JNJ7Cramer's game plan: This week, forecasts are more important than earnings ( 3:10:00 PM
JNJ7What Happened in the Stock Market Today ( 2:11:00 PM
JNJ7Apple Expands in Healthcare, Partners Johnson & Johnson ( 12:16:00 PM
JNJ7Apple Watch and Johnson & Johnson Team Up for Heart Study ( 10:42:00 AM
JNJ7Walmart and CVS ink a deal, American Express falls short, Apple partners with pharma giant ( 7:18:00 AM
JNJ7Johnson & Johnson to wield Apple Watch for health-tech study ( 7:12:00 AM
JNJ7Johnson & Johnson Is Trying to Recover From Plunge ( 5:11:00 AM
JNJ7Apple, Johnson & Johnson Team Up for Healthcare Project Involving Apple Watch ( 6:35:00 PM
JNJ7J&J (JNJ) to Commence Pharma Q4 Earnings: What to Expect ( 6:06:00 AM
JNJ7Apple and Johnson & Johnson collaborating on heart research project ( 5:43:00 AM
JNJ7Why Geron Stock Dropped 44% in 2018 ( 6:00:00 AM
JNJ7House Democrats launch drug-pricing probe into a dozen major health-care companies ( 9:09:00 AM
JNJ7Why This Group Is 'An Attractive Destination For Investors' In 2019 ( 1:14:00 PM
JNJ7J&J raises prices on around two dozen drugs ( 11:28:00 AM
JNJ7WW downgraded, Google’s board faces lawsuits, J&J hikes some prices ( 7:29:00 AM
JNJ7Surgeons fear pelvic mesh lawsuits will spook patients ( 4:18:00 PM
JNJ7J&J raises U.S. prices on around two dozen drugs ( 3:27:00 PM
JNJ7JP Morgan's Dimon hosted a private dinner for pharma executives, and a major topic was Amazon ( 10:29:00 AM
JNJ7Why Johnson & Johnson Stock Fell 12% in December ( 8:36:00 AM
JNJ7The Zacks Analyst Blog Highlights: Visa, Coca-Cola, AbbVie, Johnson & Johnson and Duke Energy ( 5:48:00 AM
JNJ7Why Johnson & Johnson May Not Have to Pay Its $4.7 Billion Court Verdict ( 2:00:00 AM
JNJ6Edited Transcript of JNJ earnings conference call or presentation 22-Jan-19 1:30pm GMT ( 5:43:00 PM
JNJ6Johnson & Johnson Reports 4th-Quarter Financial Results ( 2:02:00 PM
JNJ6What Happened in the Stock Market Today ( 2:01:00 PM
JNJ, JPM63 Things to Know at Market Close: Jamie Dimon's the King of Wall Street ( 1:28:00 PM
JNJ6Johnson & Johnson Tops Q4 Earnings Estimate, Sees 2019 Sales Near $81 Billion ( 1:24:00 PM
JNJ6J&J Predicts A Revenue Slowdown — Prodding Biotech, Pharma Stocks To Dip ( 1:18:00 PM
JNJ2AbbVie's Imbruvica Fails in Phase III Pancreatic Cancer Study ( 11:08:00 AM
JNJ2Put Up or Shut Up Time for the Stock Market After the Rally ( 8:20:00 AM
JNJ2Private equity firms circling Nestle's skin health business - sources ( 7:19:00 AM
JNJ2Q4 2018 Earnings Reports in Focus ( 7:04:00 AM
JNJ2After MLK Day Today, Markets Go for 5 Straight Up Weeks ( 6:45:00 AM
JNJ216 Stocks Jim Cramer Says Could Win from a U.S.-Chinese Trade Deal ( 7:49:00 AM
JNJ23 Stocks You Don't Realize You Use Every Day ( 10:00:00 AM
JNJ2New Rules for This Market: Cramer's 'Mad Money' Recap (Friday 1/18/19) ( 4:01:00 PM
JNJ2Cramer's game plan: This week, forecasts are more importa... ( 3:27:00 PM
JNJ2Cramer's game plan: This week, forecasts are more important than earnings ( 3:10:00 PM
JNJ2AbbVie's Imbruvica fails to meet main goal in pancreatic cancer study ( 2:45:00 PM
JNJ2Key Takeaways from Q4 Earnings Results Thus Far ( 1:10:00 PM
JNJ2The Daily Biotech Pulse: Regulatory Roadblock For Immunomedics, AdCom Split On Lexicon's Diabetes Drug ( 4:49:00 AM
JNJ2MediPharm Labs, Pure Global Cannabis, Weekend Unlimited, Plus Products, Trulieve Make Elevator Pitches ( 2:20:00 PM
JNJ2Banks Keep Stocks Moving Higher ( 6:15:00 AM
JNJ23 Weight-Loss Stocks in Focus on Rising Obesity Fears ( 5:17:00 AM
JNJ2The Daily Biotech Pulse: FDA Panel Backs Amgen's Hypertension Drug, Adamis Allergy Drug Launched In US ( 5:07:00 AM
JNJ2Health Care Stocks Face Political Risk, How I'm Playing Netflix: Market Recon ( 5:11:00 AM
JNJ2Is Teva Pharmaceutical Industries Limited Stock a Bargain? ( 3:00:00 PM
JNJ2U.S. lawmaker launches investigation into pharma drug pricing ( 1:08:00 PM
JNJ2House Dems announce sweeping investigation of drug pricing ( 9:42:00 AM
JNJ2A Look at Dow ETF Ahead of Q4 Earnings ( 7:59:00 AM
JNJ2Stock Market Power Rankings: Amazon Back on Top ( 9:00:00 AM
JNJ2Here's Why Arrowhead Pharmaceuticals Shot 237.5% Higher in 2018 ( 6:07:00 AM
JNJ2Why This IBD Stock Of The Day Broke Out Despite Biotech Turbulence ( 1:14:00 PM
JNJ24 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2019 ( 3:22:00 AM
JNJ24 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2019 ( 3:22:00 AM
JNJ2Surgeons fear pelvic mesh lawsuits will spook patients ( 4:19:00 PM
JNJ220 Women Set To Dominate The International Cannabis Space In 2019 ( 10:55:00 AM
JNJ2Dr. Paul Janssen Award for Biomedical Research Issues 2019 Call for Nominations to Celebrate Champions of Science ( 7:24:00 AM
JNJ2Karyopharm Files MAA for Myeloma Candidate Selinexor in EU ( 6:45:00 AM
JNJ2Does Eli Lilly's $8 Billion Splurge Make Array BioPharma a Buy Now? ( 5:25:00 AM
JNJ2Innovation Puts Medtronic in the Lead ( 4:00:00 AM
JNJ1J&J, U.S. states settle hip implant claims for $120 million ( 4:11:00 PM
JNJ1'Be careful about how much you sell' at these levels, war... ( 3:48:00 PM
JNJ1Cramer warns, 'careful about how much you sell' at these ... ( 3:32:00 PM
JNJ1'Be careful about how much you sell' at these levels, warns Jim Cramer ( 3:11:00 PM
JNJ1Abbott Laboratories Expected to Earn 81 cents a Share ( 2:26:00 PM
JNJ1Arconic and Stanley Black and Decker slide while eBay leaps ( 1:40:00 PM
JNJ1US STOCKS-Wall St drops as economic outlook, corporate forecasts sour ( 1:36:00 PM
JNJ1Dow Sinks as Global Growth Warnings Rattle Wall Street, Nasdaq Tumbles Over 2% ( 1:06:00 PM
JNJ1Jim Cramer: What Are We to Make of Today's Market Decline? ( 12:59:00 PM
JNJ0[$$] Johnson & Johnson to Use Apple Watch App for Heart-Health Study ( 4:29:00 PM
JNJ-2[$$] Another Reason to Worry About Johnson & Johnson ( 4:55:00 PM
JNJ-2[$$] Johnson & Johnson Expects Sales Growth to Slow ( 4:54:00 PM

WEBSITE DISCLAIMER:  Puget Investors and Vertical Financial Systems, Inc are not registered investment advisers, broker/dealers, or research analysts/organizations. The content on this website is issued solely for information purposes and should not to be construed as an offer to buy, sell, or trade in any way, any security mentioned herein.

All information presented on this website is believed to be reliable and written in good faith, but no representation or warranty, expressed or implied is made as to their accuracy, completeness or correctness. You are responsible for doing your own research before investing in any securities mentioned herein. Readers are urged to consult with their own independent financial advisors with respect to any investment. Neither Vertical Financial Systems, Inc, nor its officers or employees accept any liability whatsoever for any direct or consequential loss arising from any use of information on this website.

Past performance is not a guarantee of future performance or accuracy. Rating calculations and methodology may change at any time, and we reserve the right to make changes which may impact the accuracy of the model without prior notice to anybody.

Be advised that employees and officers of Vertical Financial Systems, Inc and may hold positions in the securities mentioned in this website.
Website Operated by Vertical Financial Systems, Inc